Tenax Therapeutics, Inc. (TENX) Stock Forecast
TENX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.10 / 5 from 10 analysts
- Price target
- $12.56 average of analyst targets
- Upside to target
- +823.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.35
- 52-week range
- $1.36 – $18.32
TENX analyst ratings
10 analystsNumber of analysts at each rating.
TENX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TENX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.39 | −$0.33 | −$0.40 | +10.0% | 7 |
| Current fiscal year (2026) | −$1.45 | −$1.75 | −$1.15 | −$1.34 | −8.4% | 9 |
| Next fiscal year (2027) | −$1.50 | −$1.74 | −$1.29 | −$1.45 | −3.3% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TENX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
TENX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TENX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.36 | −$0.36 | −$0.36 | −$0.36 | −5.7% | 4 up · 1 down |
| Current fiscal year (2026) | −$1.43 | −$1.43 | −$1.45 | −$1.45 | −$1.45 | +1.5% | 4 up · 2 down |
| Next fiscal year (2027) | −$1.39 | −$1.46 | −$1.50 | −$1.50 | −$1.50 | +7.6% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TENX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TENX beat in 10 of 12.
What analysts expect from TENX
10 analysts cover Tenax Therapeutics; their consensus rating is buy (4.10 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.56, 823.2% above the latest close of $1.36. Analysts expect earnings of −$1.45 per share for 2026, −8.4% from a year earlier. For 2027 the average estimate is −$1.50 per share. Tenax Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: TENX income statement, TENX key metrics, TENX chart. See the TENX stock overview for the latest quote and news.
TENX forecast FAQ
What is Tenax Therapeutics's price target?
The average analyst price target for Tenax Therapeutics is $12.56, 823.2% above the latest close of $1.36.
Is Tenax Therapeutics a buy, hold or sell?
Of 10 analysts covering Tenax Therapeutics, 5 rate it a strong buy, 1 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tenax Therapeutics's EPS forecast?
Analysts forecast −$1.45 per share for 2026 (range −$1.75 to −$1.15); for 2027 the estimate is −$1.50.
When does Tenax Therapeutics report earnings?
Tenax Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.35.
Does Tenax Therapeutics usually beat earnings estimates?
Tenax Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.